The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
SmithD.C.Chemotherapy for hormone refractory prostate cancer.Urol Clin North Am.1999; 26(2): 323–31.
2.
DowlingA.J., CzaykowskiP.M., KrahnM.D.Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: Prognostic factors and generalizability of a multicenter trial to clinical practice.J Urol.1999; 163(5): 1481–5.
3.
BloomfieldD.J., KrahnM.D., NeogiT.Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: Based on a Canadian randomized trial with palliative end points.J Clin Oncol.1998; 16(6): 2272–9.
4.
MooreM.J., OsobaD., MurphyK.Use of palliative end points to evaluate the effects of mitoxantrone and lowdose prednisone in patients with hormonally resistant prostate cancer.J Clin Oncol.1994; 12: 689–94.
5.
TannockI.F., OsobaD., StocklerM.R.Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points.J Clin Oncol.1996; 14(6): 1756–64.
6.
GregurichM.A.Phase III study of mitoxantrone/low-dose prednisone vs low-dose prednisone alone in patients with asymptomatic hormone-refractory carcinoma of the prostate [abstract 1321].Proc Am Soc Clin Oncol.2000; 19: 336.
7.
OsborneC.K., DrelichmanA., Von HoffD.D.Mitoxantrone: Modest activity in a phase II trial in advanced prostate cancer.Cancer Treat Rep.1983; 67(12): 1133–5.
8.
KantoffP.W., HalabiS., ConawayM.Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: The results of CALGB 9182 study.J Clin Oncol.1999; 2506–13.
9.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–9.
10.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
11.
NCCN antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Version 2000.Rockledge, PA: National Comprehensive Cancer Network; 2000.
12.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17: 2971–94.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ., BalducciL.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34: 1857–64.
17.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors.Curr Opin Hematol.1999; 6: 145–51.
18.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care.Eur J Cancer.2000; 36: S15–S21.
19.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35: 57–74.
20.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: PerryM.C., ed. The Chemotherapy Sourcebook.3rd ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 494–504.
21.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
22.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24: 969–89.
